Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)-Reference-Cited by-同舟云学术

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

Published:2014-12 Issue:18 Volume:50 Page:3116-3124
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Trouilloud Isabelle,Dupont-Gossard Anne-Claire,Malka David,Artru Pascal,Gauthier Mélanie,Lecomte Thierry,Aparicio Thomas,Thirot-Bidault Anne,Lobry Céline,Asnacios Amani,Manet-Lacombe Sophie,Fein Francine,Dubreuil Olivier,Landi Bruno,Zaanan Aziz,Bonnetain Franck,Taïeb Julien

Funder

Pfizer

AGEO

AROLD

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Medical treatment of pancreatic cancer: new hopes after 10years of gemcitabine;Trouilloud;Clin Res Hepatol Gastroenterol,2011

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma;The Oncologist;2024-09-03

3. S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL;Zeitschrift für Gastroenterologie;2022-11

4. Systemic Therapy for Metastatic Pancreatic Cancer;Current Treatment Options in Oncology;2021-10-19

5. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial;Journal of Clinical Oncology;2021-10-10